CBTp
Core Mechanism
Normalizing psychotic experiences + examining evidence for beliefs + reducing distress associated with symptoms
Ontology
Psychotic symptoms exist on a continuum; distress is driven by appraisal of experiences, not just their presence
Therapeutic Voice
"You mentioned the voices got louder this week. What was happening in your life right before they intensified?"
View of the Person
A person on a continuum of experience whose distress is driven by appraisal of symptoms, not their mere presence
Evidence
NICE: recommended for psychosis (CG178)
20+ RCTs
Cochrane review (Jones et al., 2018); Jauhar et al. (2014)
NICE-recommended. Modest but meaningful effects. Some debate about effect sizes.
Conditions
Epistemology
Blind Spots
Effect sizes debated when controlling for researcher allegiance; may underemphasize social determinants of psychosis
Contraindications
Acute crisis requiring inpatient stabilization, severe thought disorganization preventing collaborative engagement, active substance intoxication, client refusal or distress from discussing psychotic experiences
Training
CBT foundation + psychosis-specific adaptations. Training 2-5 days + supervision
No single body; Beck Institute CBTp track
16-35 hrs + supervised cases
$1K-3K
Equity & Cultural Adaptations
Philosophical Roots
Jaspers (form vs. content of psychotic experience); continuum models of psychosis; social constructionism (what counts as delusional is partly social); anti-psychiatry echoes (Laing, Szasz)
Related Modalities
Controversies & Ethical Concerns
Ongoing debate about effect sizes when controlling for researcher allegiance and blinding; critics argue CBTp has been ‘oversold’ for psychosis
Jauhar et al. (2014) published a meta-analysis in the British Journal of Psychiatry finding only small effect sizes for CBTp on positive symptoms (d=0.25) and negative symptoms (d=0.13), with effects shrinking further when controlling for blinding bias. The paper triggered a sustained debate about whether CBTp’s benefits for core psychotic symptoms had been overstated in clinical guidelines.
CBTp advocates (Birchwood, Peters, and others) responded that the meta-analysis used overly broad outcome measures (PANSS total scores) rather than targeted symptom measures, and that CBTp primarily targets distress associated with psychotic experiences rather than symptom elimination. Subsequent meta-analyses found stronger effects for specific targets like delusions.
McKenna and Kingdon (2014) argued in BMJ that CBTp had been ‘oversold’ as a treatment for schizophrenia. Laws et al. (2018) extended the critique, finding no significant benefit for quality of life and non-significant effects on functioning at follow-up. The debate highlighted how NICE continued to recommend CBTp despite effect sizes comparable to treatments considered insufficiently supported for other conditions.
CBTp remains recommended by NICE (2014), and defenders argue the debate reflects healthy scientific discourse rather than a fundamental problem. The intervention continues to evolve, with third-wave approaches and targeted interventions for specific symptoms showing stronger effects than generic CBTp protocols.
Clinical Vignettes
See how CBTp formulates these cases:
Test Yourself
CBTp vs. standard CBT?
Show answer
Avoids directly challenging delusions; explores appraisals and reduces distress.